Last updated November 10, 2026
Our verdict
GLP-3RT Oral Spray is the pick for anyone who wants a ready-to-use format. The compound and the lab documentation are the same as the vial. What is missing is published data on this delivery route, so we score it below the vial.
Scored by our editors against fixed criteria. This is an editorial rating, not an average of customer reviews.
Specifications
| Class | GLP-1 / GIP / glucagon triple agonist |
|---|---|
| Form | Oral spray, 15 mL |
| Purity | 99%+ |
| Published route data | None for oral spray delivery |
What the published trials show
GLP-3RT is listed under the research code LY3437943, the molecule known in the literature as retatrutide. Its human data is recent and still growing.
| Study | Who | Length | Average weight change (top dose) | Placebo |
|---|---|---|---|---|
| Phase 2 (NEJM 2023) | 338 adults with obesity | 48 weeks | -24.2% | -2.1% |
| TRIUMPH-2 (topline, July 2026) | 1,152 adults with type 2 diabetes | 80 weeks | -20.8% | -4.0% |
| TRIUMPH-3 (topline, July 2026) | 1,949 adults with severe obesity and heart disease | 80 weeks | -22.6% | -3.2% |
The developer has said it plans to file with the FDA in the first quarter of 2027. Until a decision, the molecule is investigational and not approved anywhere.
Reported side effects
Mostly digestive and dose-related: nausea, diarrhea, vomiting and reduced appetite. In TRIUMPH-3, diarrhea was reported by 24.4% of the 12 mg group against 8.7% on placebo, and 13.5% stopped because of side effects against 4.8% on placebo. Altered skin sensation (dysesthesia) was reported by about 6% on the drug against 1.3% on placebo.
About the spray format
Every trial quoted on this page delivered the molecule by subcutaneous injection once a week. We found no published human data on nasal or oral-spray delivery of this compound, so there is no trial evidence on how much of it is absorbed that way. That gap is the main reason sprays score lower than vials in our ranking. If the format matters more to you than the evidence base, this is the convenient option. If the evidence matters more, look at the vial.
How it compares
| GLP-3RT Oral Spray | GLP-2T Vial | |
|---|---|---|
| Receptors | GLP-1, GIP, glucagon | GLP-1, GIP |
| From | $220.00 | $76.00 |
| Editorial score | 4.1/5 | 4.7/5 |
Full GLP-3RT vs GLP-2T comparison →
Customer reviews
No verified customer reviews have been published for this product yet. Ordered it? Send us your review and we will publish it here with your permission.
FAQ
What is GLP-3RT Oral?
GLP-3RT Oral is a triple agonist acting on GLP-1, GIP and glucagon receptors sold by US Peptide Labs as a research compound in a spray format.
How much does GLP-3RT Oral Spray cost?
From $220.00 at our last check. The store takes 5% off 2 or more units and 10% off 5 or more.
Does it come with a certificate of analysis?
Yes. US Peptide Labs publishes lot-specific COAs from an independent lab, AxisPharm, and prints a QR code on each vial that opens the certificate for that lot.
Is GLP-3RT Oral FDA approved?
No. It is a research chemical sold for laboratory use only and is not approved to diagnose, treat, cure or prevent any disease.
Where does it ship from?
From a US facility with tracking. Orders of $70 or more ship free, and they do not pass through customs.